Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 25:8:100353.
doi: 10.1016/j.ijcchd.2022.100353. eCollection 2022 Jun.

Selexipag in patients with complex or uncorrected congenital heart disease: Single centre experience

Pablo Meras  1 , Carlos Merino  1 , Ana Elvira Gonzalez-Garcia  1 , Jose Ruiz-Cantador  1
Affiliations

Selexipag in patients with complex or uncorrected congenital heart disease: Single centre experience

Pablo Meras et al. Int J Cardiol Congenit Heart Dis. .
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
A-B. Changes in WHO functional class before and after (6–12 months) starting treatment with selexipag. N at baseline = 14. N at follow-up = 13 (one patient excluded from follow-up as had early discontinuation of treatment). Patients with clinical improvement (n = 8) comprised: 4 Eisenmenger syndrome, 2 systemic-to-pulmonary shunt and 2 corrected defects. Patient with clinical worsening (n = 1) had a small coincidental defect. C. Number of patients with target dose of selexipag. FC: functional class. bid: twice daily.
Fig. 2
Fig. 2
Survival free from PAH complications (combined end-point including death, hospital admission, lung transplant or initiation of parenteral prostacyclin therapy). A: Global population. B: Stratified by subgroup of shunt (pre-tricuspid vs. complex). Six patients had an event: 4 had complex CHD with ES, and 2 had simple pre-tricuspid defects (1 patient with persistent systemic-to-pulmonary shunt and 1 patient with ES). CHD: congenital heart disease.
See this image and copyright information in PMC

References

    1. McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477–1482. doi: 10.1161/01.CIR.0000029100.82385.58. - DOI - PubMed
    1. Beghetti M., Channick R.N., Chin K.M., et al. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. Eur J Heart Fail. 2019;21(3):352–359. doi: 10.1002/ejhf.1375. - DOI - PMC - PubMed
    1. El-Kersh K., Suliman S., Smith J.S. Selexipag in congenital heart disease-associated pulmonary arterial hypertension and Eisenmenger syndrome: first report. Am J Therapeut. 2018;25(6):e714–e715. doi: 10.1097/MJT.0000000000000727. - DOI - PubMed
    1. Demerouti E.A., Karyofyllis P., Apostolopoulou S.C. Use of the prostacyclin receptor agonist selexipag in patients with pulmonary arterial hypertension associated with eisenmenger syndrome. Can J Cardiol. 2021;37(8):1286–1288. doi: 10.1016/j.cjca.2021.01.023. - DOI - PubMed
    1. Blissett S., Blusztein D., Mahadevan V.S. Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series. Eur Heart J Case Rep. 2020;4(6):1–7. doi: 10.1093/ehjcr/ytaa320. - DOI - PMC - PubMed

LinkOut - more resources